Skip to content
DataLookout
Menu

NCT07947043

Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

ORR
Timeframe: Up to 12 months after first dose

Secondary (3)

PFS
DOR
OS

Arms and interventions

Autologous Tumor-Infiltrating Lymphocyte InjectionExperimental

Autologous Tumor-Infiltrating Lymphocyte Injection with a single administration dose of 1×10¹⁰ (±20%), 3×10¹⁰ (±20%), and 5×10¹⁰ (±20%) cells per person per administration respectively.

Biologicals: Autologous Tumor-Infiltrating Lymphocyte Injection

Sites

1 site in 1 country

  • Tongji HospitalWuhan, Hubei, China